Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 8/20 | 0.64 |
| ▸ | NOS3 | P29474 | 4/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8275779 | 0.96 | NOS1 (0.62) | NOS1NOS3KCNH2KDM4EMEN1 | |
| SCHEMBL8275735 | 0.96 | NOS1 (0.62) | NOS1NOS3KCNH2KDM4EMEN1 | |
| SCHEMBL8275738 | 0.95 | NOS1 (0.61) | NOS1NOS3KCNH2KDM4EMEN1 | |
| SCHEMBL8276047 | 0.89 | NOS1 (0.66) | NOS1NOS3KCNH2MEN1GAA | |
| SCHEMBL8275828 | 0.86 | NOS1 (0.60) | NOS1NOS3KCNH2KDM4EMEN1 | |
| SCHEMBL8275894 | 0.86 | NOS1 (0.60) | NOS1NOS3KCNH2KDM4EMEN1 | |
| SCHEMBL8276050 | 0.85 | NOS1 (0.63) | NOS1NOS3KCNH2KDM4EMEN1 | |
| SCHEMBL8276002 | 0.85 | NOS1 (0.63) | NOS1NOS3KCNH2KDM4EMEN1 | |
| SCHEMBL5077795 | 0.85 | NOS1 (0.71) | NOS1NOS3KCNH2CD274PDCD1 | |
| SCHEMBL8275814 | 0.85 | NOS1 (0.57) | NOS1NOS3CD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | NOS3, NOS1, NOS2 | NOS1 2/4885NOS3 1/4885KCNH2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.